Zentiva Amends Offer for APONTIS PHARMA Shares

Zentiva AG has waived the minimum acceptance condition in its public purchase offer to acquire APONTIS PHARMA AG shares. The acceptance period remains unchanged, ending on 21 November 2024 at midnight CET. This move aims to facilitate the acquisition process.

Zentiva, based in Frankfurt, offers EUR 10.00 per share, marking a 52.9% premium over APONTIS PHARMA's share price on 15 October 2024. As of 19 November, 55.76% of the voting share capital has accepted the offer. Paragon, APONTIS PHARMA's largest shareholder, has also agreed to sell its 37.5% stake.

The necessary regulatory clearances have been secured. Upon settlement, APONTIS PHARMA's management will withdraw the company's shares from open market trading, with no separate delisting offer required.